Debt Financing (Details)	9 Months Ended					9 Months Ended			9 Months Ended				9 Months Ended				9 Months Ended
	Sep. 30, 2012 USD ($)	Sep. 30, 2012 EUR (€)		Sep. 30, 2011 EUR (€)	Dec. 31, 2011 EUR (€)	Sep. 30, 2012 Norwood Secured Loan [Member] EUR (€)	Nov. 01, 2012 Norwood Secured Loan [Member]	Sep. 30, 2012 Norwood Secured Loan [Member] USD ($)	Sep. 30, 2012 Norwood Secured Loan [Member] 04/03/2009 [Member] EUR (€)		Sep. 30, 2012 Norwood Secured Loan [Member] 04/03/2009 [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 08/04/2011 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 11/08/2011 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 02/17/2012 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 12/10/2007 [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 12/10/2007 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 01/22/2008 [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 01/22/2008 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 04/25/2008 [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 04/25/2008 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 06/30/2008 [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 06/30/2008 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 11/18/2008 [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 11/18/2008 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 02/9/2009 [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 02/9/2009 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 06/15/2009 [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 06/15/2009 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 10/13/2009 [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 10/13/2009 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 12/18/2009 [Member] USD ($)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 12/18/2009 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 04/09/2012 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. [Member] 05/04/2012 [Member] EUR (€)		Sep. 30, 2012 Eardley Holding A.G. [Member] USD ($)		Sep. 30, 2012 Eardley Holding A.G. [Member] EUR (€)		Sep. 30, 2012 Eardley Holding A.G. [Member] 08/04/2011 [Member] EUR (€)		Sep. 30, 2012 Eardley Holding A.G. [Member] 11/08/2011 [Member] EUR (€)		Sep. 30, 2012 Eardley Holding A.G. [Member] 02/17/2012 [Member] EUR (€)		Sep. 30, 2012 Eardley Holding A.G. [Member] 06/23/2006 [Member] USD ($)		Sep. 30, 2012 Eardley Holding A.G. [Member] 06/23/2006 [Member] EUR (€)		Sep. 30, 2012 Eardley Holding A.G. [Member] 06/15/2009 [Member] USD ($)		Sep. 30, 2012 Eardley Holding A.G. [Member] 06/15/2009 [Member] EUR (€)		Sep. 30, 2012 Eardley Holding A.G. [Member] 04/09/2012 [Member] EUR (€)		Sep. 30, 2012 Eardley Holding A.G. [Member] 05/04/2012 [Member] EUR (€)		Sep. 30, 2012 Anglo Irish Bank S.A. [Member] 10/21/2007 [Member] USD ($)		Sep. 30, 2012 Anglo Irish Bank S.A. [Member] 10/21/2007 [Member] EUR (€)		Sep. 30, 2012 Von Meyenburg [Member] 08/03/2009 [Member] USD ($)		Sep. 30, 2012 Von Meyenburg [Member] 08/03/2009 [Member] EUR (€)		Sep. 30, 2012 Round Enterprises Ltd. and Eardley Holding A.G. [Member]
Short term and long term debt instruments [Line Items]
Carrying value of convertible notes		€ 31,064,000
Issuance date of debt convertible						Apr. 19, 2012							Feb. 10, 2012																																																																																May 04, 2012
Principal balance		1,165,000		2,319,000									1,100,000
Face Amount	190					2,500,000									1,200																																																300
Maturity Date	Nov. 30, 2012	Nov. 30, 2012											Dec. 16, 2011																																																																																Nov. 30, 2012
Principal balance converted to shares (in shares)	19,301,474	19,301,474
Fixed EUR/USD Rate for Conversion Price									1.2812	[1]			1.3260										1.4429	[2]	1.4429	[2]	1.4629	[2]	1.4629	[2]	1.5889	[2]	1.5889	[2]	1.5380	[2]	1.5380	[2]	1.2650	[2]	1.2650	[2]	1.2940	[2]	1.2940	[2]	1.4045	[2],[3]	1.4045	[2],[3]	1.4854	[2]	1.4854	[2]	1.4338	[2]	1.4338	[2]																			1.4300	[2],[3]	1.4300	[2],[3]					1.4090	[2],[4]	1.4090	[2],[4]	1.4400	[2]	1.4400	[2]
Conversion price											$ 0.50	[1]			$ 0.08								$ 0.50	[2]			$ 0.50	[2]			$ 0.50	[2]			$ 0.50	[2]			$ 0.50	[2]			$ 0.50	[2]			$ 0.80	[2],[3]			$ 0.25	[2]			$ 0.25	[2]																	$ 0.10	[2],[5]			$ 0.80	[2],[3]							$ 0.50	[2],[4]			$ 0.80	[2]
Amount of payment of accrued interest due						402,000
Percentage reduction in price per share (in hundredths)						10.00%																																																																																							10.00%
Amount of investment by new investors, minimum								20,000
Details of the convertible notes loans and contingent liabilities [Abstract]
1st-Issue Date									Apr. 03, 2009	[1]			Sep. 30, 2012	[6]			Aug. 04, 2011	[7]	Nov. 08, 2011	[6]	Feb. 17, 2012	[6]	Dec. 10, 2007	[2]	Dec. 10, 2007	[2]	Jan. 22, 2008	[2]	Jan. 22, 2008	[2]	Apr. 25, 2008	[2]	Apr. 25, 2008	[2]	Jun. 30, 2008	[2]	Jun. 30, 2008	[2]	Nov. 28, 2008	[2]	Nov. 28, 2008	[2]	Feb. 09, 2009	[2]	Feb. 09, 2009	[2]	Jun. 15, 2009	[2],[3]	Jun. 15, 2009	[2],[3]	Oct. 13, 2009	[2]	Oct. 13, 2009	[2]	Dec. 18, 2009	[2]	Dec. 18, 2009	[2]	Apr. 19, 2012	[6]	May 04, 2012	[6]	Sep. 30, 2012	[6]	Sep. 30, 2012	[6]	Aug. 04, 2011	[7]	Nov. 08, 2011	[6]	Feb. 17, 2012	[6]	Jun. 23, 2006	[2],[5]	Jun. 23, 2006	[2],[5]	Jun. 15, 2009	[2],[3]	Jun. 15, 2009	[2],[3]	Apr. 19, 2012	[6]	May 04, 2012	[6]	Oct. 21, 2007	[2],[4]	Oct. 21, 2007	[2],[4]	Aug. 03, 2009	[2]	Aug. 03, 2009	[2]
Principal Amount, Short Term		26,466,000							2,500,000	[1]			200,000	[6]			933,000	[7]	400,000	[6]	1,000,000	[6]			1,500,000	[2]			1,500,000	[2]			2,000,000	[2]			1,500,000	[2]			1,200,000	[2]			1,500,000	[2]			5,500,000	[2],[3]			2,000,000	[2]			2,200,000	[2]	322,000	[6]	480,000	[6]			50,000	[6]	233,000	[7]	100,000	[6]	200,000	[6]			148,000	[2],[5]			100,000	[2],[3]	80,000	[6]	120,000	[6]			500,000	[2],[4]			200,000	[2]
Change in loan interest rate (in hundredths)							10.00%
Interest Rate (in hundredths)											5.00%	[1]			10.00%	[6]	10.00%	[7]	10.00%	[6]	10.00%	[6]	10.00%	[2]	10.00%	[2]	10.00%	[2]	10.00%	[2]	10.00%	[2]	10.00%	[2]	10.00%	[2]	10.00%	[2]	10.00%	[2]	10.00%	[2]	10.00%	[2]	10.00%	[2]	10.00%	[2],[3]	10.00%	[2],[3]	5.00%	[2]	5.00%	[2]	5.00%	[2]	5.00%	[2]	10.00%	[6]	10.00%	[6]	10.00%	[6]	10.00%	[6]	10.00%	[7]	10.00%	[6]	10.00%	[6]	10.00%	[2],[5]	10.00%	[2],[5]	10.00%	[2],[3]	10.00%	[2],[3]	10.00%	[6]	10.00%	[6]	10.00%	[2],[4]	10.00%	[2],[4]	10.00%	[2]	10.00%	[2]
Conversion Price (stated) (in dollars per share)											$ 0.50	[1]			$ 0.08								$ 0.50	[2]			$ 0.50	[2]			$ 0.50	[2]			$ 0.50	[2]			$ 0.50	[2]			$ 0.50	[2]			$ 0.80	[2],[3]			$ 0.25	[2]			$ 0.25	[2]																	$ 0.10	[2],[5]			$ 0.80	[2],[3]							$ 0.50	[2],[4]			$ 0.80	[2]
Fixed EUR/USD Rate for Conversion Price									1.2812	[1]			1.3260										1.4429	[2]	1.4429	[2]	1.4629	[2]	1.4629	[2]	1.5889	[2]	1.5889	[2]	1.5380	[2]	1.5380	[2]	1.2650	[2]	1.2650	[2]	1.2940	[2]	1.2940	[2]	1.4045	[2],[3]	1.4045	[2],[3]	1.4854	[2]	1.4854	[2]	1.4338	[2]	1.4338	[2]																			1.4300	[2],[3]	1.4300	[2],[3]					1.4090	[2],[4]	1.4090	[2],[4]	1.4400	[2]	1.4400	[2]
Accrued Interest		7,171,000
Total Long Term Convertible Notes to Related Parties		33,637,000
Norwood Contingent Liability		6,323,000	[8]
TOTAL LOANS, NOTES, AND CONTINGENT LIABILITY		39,960,000
Required future payments on long-term debt [Abstract]
Current portion of notes payable to related Parties		33,637,000			5,711,000
Contingent liability to Norwood (milestones and royalties)		6,323,000			5,753,000
Contingent on ability to repay		0			25,331,000
TOTAL LOANS, NOTES, AND CONTINGENT LIABILITY		39,960,000
Debt instrument face amount	190					2,500,000									1,200																																																300
Debt collateral description									The note is secured against 1/3rd of Bestewil common stock																																						The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV		The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV
Debt amendment payment amount									402,000
Debt repayment and conversion price description	The repayment of the loan will be half in shares and half in cash and is contingent on an investment in the Company of not less than $20,000 by new investors. The conversion price is determined by reducing by 10% the price per share of the Company's common stock paid by the investors in connection with such an investment. In the case Mymetics is not able to close the investment of not less than $20,000 before or on September 30, 2012, the terms of the loan will revert to the original terms and the loan and accrued interest becomes immediately payable	The repayment of the loan will be half in shares and half in cash and is contingent on an investment in the Company of not less than $20,000 by new investors. The conversion price is determined by reducing by 10% the price per share of the Company's common stock paid by the investors in connection with such an investment. In the case Mymetics is not able to close the investment of not less than $20,000 before or on September 30, 2012, the terms of the loan will revert to the original terms and the loan and accrued interest becomes immediately payable
Conversion feature minimum investment amount	$ 20,000
Conversion price reduction percentage (in hundredths)	10.00%	10.00%

[1] Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company issued to Norwood Immunology Limited (“NIL”) a convertible redeemable note (the “Note”) in the principal amount of E2,500 with a maturity date of April 1st, 2012 and bearing interest at 5% per annum. The note is secured against 1/3rd of Bestewil common stock. On April 19, 2012, Mymetics and (NIL) agreed to an amendment to the E2,500 loan agreement. The amended agreement resulted in the payment E402 on April 20, 2012 covering all the accrued interest due to NIL and a delay of the repayment of the E2,500 loan until September 30, 2012, with a 5% interest per annum starting April 20, 2012. The repayment of the loan will be half in shares and half in cash and is contingent on an investment in the Company of not less than $20,000 by new investors. The conversion price is determined by reducing by 10% the price per share of the Company’s common stock paid by the investors in connection with such an investment. In the event Mymetics is not able to close the investment of not less than $20,000 from new investors on or before September 30, 2012, the loan and accrued interest become immediately payable. On October 31, 2012, Mymetics agreed with NIL to amend the terms and conditions of the second amendment signed on September 21, 2012. The deadline of October 31, 2012 for Mymetics to close the investment has been moved to December 31, 2012. The interest rate of the loan has changed from 5% to 10% starting from November 1, 2012 and Mymetics will pay E109 to NIL by November 16, 2012, which reflects the interest on the loan until December 31, 2012.

[2] The loans expire the earlier of (i) November 30, 2012 or (ii) upon an event of default. The loans are secured by the IP assets of the Company.

[3] The loans expire the earlier of (i) November 30, 2012 or (ii) upon an event of default. The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV.

[4] Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

[5] Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190

[6] The loans expire the earlier of (i) November 30, 2012 or (ii) upon an event of default.

[7] The loans expire the earlier of (i) November 30, 2012 or (ii) upon an event of default. The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively. These notes are under negotiation as they are expiring.

[8] Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company is committed to make further payments to NIL in the event that certain stated milestones for the development of vaccines are achieved. These have been considered on a risk probability basis.